Navigation Links
News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics

SAN MARINO, Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour -- published in the June issue of the International Journal of Oncology, Vol.30, pp. 1297-1307 -- documents the histologic features of tumor destruction observed in chemo-resistant cancers following intravenous infusions of Rexin-G(TM), the world's first tumor-targeted genetic medicine for cancer therapy. In other words, this paper documents the unprecedented efficacy of targeted gene delivery in the tragic battlefield of metastatic cancer, where all other treatments have historically failed.


Previously, Gordon et al. reported that intravenous infusions of Rexin-G, a pathotropic nanoparticle bearing a cyto-ablative construct, induced tumor regression, reduced tumor burden, and improved survival, while enhancing the overall quality-of-life of patients with otherwise intractable cancers (2006). In this new clinical paper, the authors describe the major histopathologic and radiologic features that are characteristic of solid tumors under the onslaught of Rexin-G administered as a single therapeutic agent. To further promote tumor eradication and enhance cancer survival, the potential of an auxiliary gene transfer strategy was explored, specifically intended to induce cancer auto-immunization. This immunization strategy uses Rexin-G in combination with Reximmune-C(TM) a tumor-targeted expression vector bearing a granulocyte macrophage colony stimulating factor (GM-CSF) gene. The intent of this two-step approach is to bring a complement of cells involved in humoral and cell-mediated immunity in close proximity to the immunizing tumor antigens in a concerted effort to assist in tumor eradication and to promote a cancer vaccination in situ. Fea turing more than 40 histological plates, from surgical biopsies and excised tumors, the paper provides indisputable proofs-of-principle for both tumor destruction and active immunization induced by the targeted gene transfer approach.

The literary allegory of Le Morte du Tumour and the characterization of metastatic cancer as a personal battlefield is apt, for in the words of Dr. Frederick L. Hall, President and CEO of Epeius -- "In each and every cancer patient extends their very own impedimenta, which deepens and exacerbates with time and ineffectual apothecary. The scientists and physicians at Epeius Biotechnologies are proud to have participated in the historic events that brought these first targeted genetic medicines safely and conscientiously across the threshold of history, bringing hard science gently to the bedside."

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. Credited with innovations ranging from oncogene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling platform technologies for the benefit of cancer patients worldwide. Rapid advances in clinical drug development provide Epeius with a unique opportunity for early revenues from the exportation and sale of its lead product to the Philippines and reciprocating Southeast Asian countries -- thus demonstrating the high growth potential of a small biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.

To learn more about Rexin-G and Epeius' pipeline of proprietary compounds currently available for partnership or clinical trials, please visit us at

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).

CONTACT: Amy Blackley, Ph.D., of Porter Novelli Life Sciences,+1-619-849-6008, , for Epeius Biotechnologies

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
3. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
4. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
5. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
6. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
7. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
8. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
9. Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
10. Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients Published
11. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
Post Your Comments:
(Date:11/26/2015)... India , November 27, ... --> --> ... personal emergency response system (PERS) ... steadily for 5 years with ... region expected to see a ...
(Date:11/26/2015)... WILMINGTON, North Carolina , 26 november ... Laboratories, Inc. (AAIPharma/CML) kondigt de geplande investering ... de uitbreiding van de laboratoria en het ... . De uitbreiding zal resulteren in ... waarmee wordt voldaan aan de groeiende behoeften ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The ... and prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, ... and helped advance the healthcare industry as a whole through their advocacy and ...
(Date:11/26/2015)... ... ... Inevitably when people think Thanksgiving, they also think Holiday sales and start ... and Cyber Monday massage chair sales to receive the best pricing on ... find the best massage chair deals, they can see all of the coupons in ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their ... surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for ... excited to rebuild lives and it’s an honor to have served all of these ...
(Date:11/25/2015)... OAK BROOK, Ill. (PRWEB) , ... November 25, ... ... sometimes larger and potentially more aggressive than those found on mammography, according to ... cases MRI findings of additional cancers not seen on mammography may necessitate a ...
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... ... launched offering factory direct sauna parts and accessories. , Sauna accessories help ... of the bather’s style and personality. From basic styles for the purist looking ...
Breaking Medicine News(10 mins):